A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body.
ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan.
Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:ABBVIE CALL CENTER
- 电话号码:844-663-3742
- 邮箱:abbvieclinicaltrials@abbvie.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100053
- 招聘中
- Xuanwu Hospital Capital Medical University /ID# 283310
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510260
- 招聘中
- The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295
-
-
-
-
California
-
Irvine、California、美国、92614
- 招聘中
- Irvine Center for Clinical Research /ID# 277752
-
-
Colorado
-
Boulder、Colorado、美国、80301
- 招聘中
- Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
-
-
Florida
-
Bradenton、Florida、美国、34207
- 招聘中
- Key Clinical Research LLC /ID# 277800
-
接触:
- Site Coordinator
- 电话号码:941-241-5539
-
Clermont、Florida、美国、34711
- 招聘中
- K2 Medical Research - Clermont /ID# 277859
-
Lady Lake、Florida、美国、32159
- 招聘中
- K2 Medical Research - The Villages /ID# 278290
-
Stuart、Florida、美国、34997
- 招聘中
- Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
-
Wellington、Florida、美国、33414
- 招聘中
- Alzheimer's Research And Treatment Center - Wellington /ID# 277749
-
接触:
- Site Coordinator
- 电话号码:(561) 209-2400
-
Winter Park、Florida、美国、32789
- 招聘中
- Conquest Research - Winter Park /ID# 277760
-
接触:
- Site Coordinator
- 电话号码:407-916-0060
-
-
Massachusetts
-
Watertown、Massachusetts、美国、02472
- 招聘中
- Adams Clinical /ID# 277754
-
-
Tennessee
-
Cordova、Tennessee、美国、38018
- 招聘中
- Neurology Clinic - Cordova /ID# 277790
-
-
Texas
-
Dallas、Texas、美国、75231
- 招聘中
- Kerwin Medical Center /ID# 277788
-
接触:
- Site Coordinator
- 电话号码:972-433-9100
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants meeting all the following criteria for Alzheimer's disease (AD):
- In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that do not have known elevated brain amyloid based on previous amyloid positron emission tomography (PET) results.
- Participants with amyloid positron emission tomography PET scan results consistent with significant amyloid pathology (as determined by a Centiloid value of 50 or higher).
-
Participants must have a Mini-Mental State Examination (MMSE) score of 20 or higher at Screening.
Exclusion Criteria:
-
Participants with screening magnetic resonance imaging (MRI) that show evidence of another potential etiology for progressive dementia.
-
Participants who have any current serious conditions or illnesses that are not adequately controlled, or any conditions that, in the investigator's opinion, could interfere with the analyses in this study, including but not limited to psychiatric, neurologic (other than AD), cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, immunologic, or hematologic, metabolic, pulmonary, ophthalmologic, dermatologic, and/or any history of abnormal laboratory results that are indicative of significant disease(s).
-
Participants who had prior exposure to ABBV-1758 or any history of exposure to anti-amyloid beta monoclonal antibody (mAb) treatment.
-
Participants with other significant pathological findings on brain MRI at screening, including but not limited to:
- Evidence of vasogenic edema
- 4 or more microhemorrhages (defined as 10 mm or less at the greatest diameter)
- Any macrohemorrhage (defined as greater than 10 mm at the greatest diameter)
- Any superficial siderosis
- Severe white matter disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Stage A-ABBV-1758 Dose A
Participants will receive ABBV-1758 dose A once every 4 weeks (Q4W). |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758 Dose A
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage A-ABBV-1758 Dose B
Participants will receive ABBV-1758 dose B Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758 Dose B
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage A-ABBV-1758 Dose C
Participants will receive ABBV-1758 dose C Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758 Dose C
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage A-ABBV-1758 Dose D
Participants will receive ABBV-1758 dose D Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758 Dose D
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage B- ABBV-1758 - Expanded Cohort 1
Participants will receive ABBV-1758 dose determined in Stage A Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758 - Expanded Cohort 1
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage B- ABBV-1758- Expanded Cohort 2
Participants will receive ABBV-1758 dose determined in Stage A Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758- Expanded Cohort 2
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage C- ABBV-1758 - Japanese Cohort 1
Participants will receive ABBV-1758 dose determined in Stage A Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758 - Japanese Cohort 1
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage C- ABBV-1758- Japanese Cohort 2
Participants will receive ABBV-1758 dose determined in Stage A Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758- Japanese Cohort 2
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
实验性的:Stage C- ABBV-1758-Chinese Cohort
Participants will receive ABBV-1758 dose determined in Stage A Q4W. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
|
安慰剂比较:Placebo for ABBV-1758- Chinese Cohort
Participants will receive Placebo for ABBV-1758. |
Intravenous (IV) or Subcutaneous (SC) Subcutaneous (SC) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Experiencing Adverse Events (AEs)
大体时间:Up to approximately 40 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to approximately 40 weeks
|
|
Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results
大体时间:Up to approximately 40 weeks
|
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed. |
Up to approximately 40 weeks
|
|
Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)
大体时间:Up to approximately 40 weeks
|
Amyloid related imaging abnormalities represent a spectrum of magnetic resonance imaging findings primarily observed in participants undergoing treatment with anti-amyloid therapies. |
Up to approximately 40 weeks
|
|
Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements
大体时间:Up to approximately 40 weeks
|
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed. |
Up to approximately 40 weeks
|
|
Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters
大体时间:Up to approximately 40 weeks
|
12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF). |
Up to approximately 40 weeks
|
|
Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to approximately 40 weeks
|
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
Up to approximately 40 weeks
|
|
Stage A, B, and C: Change from Baseline in Brain Amyloid Load
大体时间:Up to approximately 28 Weeks
|
Measured by amyloid positron emission tomography (PET) |
Up to approximately 28 Weeks
|
|
Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
Cmax of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Time to Cmax (Tmax) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
Tmax of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
Ctrough of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
AUCtau of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
Cav,ss of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
AUCtau of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Total Body Clearance (CL) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
CL of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Apparent Clearance (CL/F) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
CL/F of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Volume of Distribution at Steady-State (Vss)
大体时间:Up to approximately 40 weeks
|
Vss of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)
大体时间:Up to approximately 40 weeks
|
Vz of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
β of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758
大体时间:Up to approximately 40 weeks
|
Terminal phase elimination half-life of ABBV-1758 |
Up to approximately 40 weeks
|
|
Stage A and C: Effective Half-Life (T1/2,eff)
大体时间:Up to approximately 40 weeks
|
T1/2,eff of ABBV-1758 |
Up to approximately 40 weeks
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- M25-804
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共享时间框架
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共享访问标准
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.